Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

HCC Risk in Hepatitis B Infection: Considerations for Treatment and Monitoring
  • CME
  • CE

Credits Available
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Registered Nurses: 0.25 Nursing contact hours
Pharmacists: 0.25 contact hours (0.025 CEUs)
Released: March 26, 2021 Expiration: March 25, 2022
Start Activity
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from:
Gilead Sciences, Inc.
Mindie H. Nguyen, MD, MAS, AGAF, FAASLD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Monitor patients with chronic hepatitis B awaiting therapy or on-therapy according to current practice guidelines

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Mindie H. Nguyen, MD, MAS, AGAF, FAASLD

Professor of Medicine
Department of Gastroenterology and Hepatology
Stanford University Medical Center
Palo Alto, California

Mindie H. Nguyen, MD, MAS, AGAF, FAASLD, has disclosed that she has received consulting fees from Alnylam, Bristol-Myers Squibb, Dynavax, Gilead Sciences, Janssen, Lab for Advanced Medicine, Novartis, and Roche and fees for non-CME/CE Services from Alnylam, Bristol-Myers Squibb, Dynavax, Gilead Sciences, and Roche.

Staff

Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer M. Blanchette, PhD, has no relevant conflicts of interest to report.
Edward King, MA

Executive Vice President

Edward King, MA, has no relevant conflicts of interest to report.
Jennifer Swanson, PharmD

Editorial Contributor

Jennifer Swanson, PharmD, has no relevant conflicts of interest to report.
Tiffany Hensley-McBain, PhD

Scientific Director

Tiffany Hensley-McBain, PhD, has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Julie Skowronski, FNP-BC
Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, pharmacists, registered nurses, and other healthcare professionals who provide care for patients at risk of or diagnosed with HBV.

Goal

The goal of this activity is to improve learners’ competence in applying guideline-based care in the management of patients with hepatitis B, by addressing common mistakes identified through the Hep B Consult Tool.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 0.25 contact hours (0.025 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-21-069-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 100% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 26, 2021, through March 25, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

HCC Risk in Hepatitis B Infection: Considerations for Treatment and Monitoring
  • CME
  • CE

Loading...
This concise MedicalMinute presentation reviews the AASLD guidelines on monitoring and treatment for patients with HBV infection, including a brief discussion of HCC risk in various patient populations.
Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Registered Nurses: 0.25 Nursing contact hours
Pharmacists: 0.25 contact hours (0.025 CEUs)
Released: March 26, 2021 Expiration: March 25, 2022

Related Content

W. Grace L. H. Wong 博士,来自 Clinical Care Options (CCO)的慢性 HBV 患者的 HCC 风险评估和跨学科管理

Grace LH Wong, 医学博士 Released: April 16, 2021

Clinical Care Options (CCO) expert commentary on incorporating family history into clinical decision-making when caring for patients with hepatitis B

Anna Christina L. dela Cruz, MD Released: April 15, 2021

Dr. Grace L. H. Wong on HCC risk assessment and interdisciplinary management of HCC in patients with chronic HBV, from Clinical Care Options (CCO)

Grace LH Wong, MD Released: April 15, 2021

Download free expert-authored slides reviewing key data and AASLD guidance on HCC risk, considerations for treatment, and HCC monitoring

Mindie H. Nguyen, MD, MAS, AGAF, FAASLD Released: March 26, 2021
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from:
Gilead Sciences, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue